Mylan NV (NASDAQ: MYL), a global pharmaceutical company, is collaborating with United States-based Gilead Sciences to expand access to the investigational antiviral remdesivir, intended for the treatment of COVID-19, it was reported on Tuesday.
The contract grants Mylan the rights to produce and distribute remdesivir in 127 low- and middle-income countries, including India. It is non-exclusive, enabling multiple licensees to ensure extensive access to this treatment, once approved as safe and effective for COVID-19 patients.
Mylan believes that it will be able to produce a bioequivalent version of remdesivir, including production of its own active pharmaceutical ingredient and the finished dosage form in sterile powder lyophilised vials for administration of the medicine by intravenous infusion.
Lilly declares Q2 2025 dividend
Bruker acquires majority stake in RECIPE to expand clinical mass spectrometry diagnostics
Emmaus Life Sciences reports drop in revenues, increased loss in 2024
L'Oréal and WHO Foundation partner to expand global skin health access